New drug found to cure cancer said to be unprofitable. DCA is non-patentable as a compound, though a patent has been filed for its use in cancer treatment. Concerns have been raised that without strong intellectual property protection, the financial incentive for drug development is reduced, and therefore clinical trials of DCA may not be funded. When faced with the high costs of getting Food and Drug Administration approval, estimated by Tufts University to exceed one billion dollars , the chance of getting DCA approved for the treatment of cancer in the United States is extremely low. This problem is highlighted in the 2007 New York Times article by Ralph Moss titled "Patents over Patients" .